MeMed BV® – Rapidly diagnose infection etiology Powered by Host Response
Is it bacterial or viral?
Now you know in 15 minutes!
Clinically Proven Accuracy in Bacterial vs. Viral Differentiation
Bacterial and viral infections often present with similar symptoms, making treatment decisions difficult. MeMed BV® uses host response data to quickly and accurately differentiate between them—empowering physicians to make faster, more informed choices and reduce unnecessary antibiotic use.
Antibiotic Misuse Is Often a Result of Diagnostic Uncertainty
Traditional diagnostic tests often rely on detecting the pathogen directly, which can be slow, unreliable, or inconclusive—especially in urgent care settings. These limitations can delay treatment decisions, contribute to antibiotic misuse, and hinder effective infection management.
Challenges with Current Bacterial vs. Viral Testing Methods
Inaccessible
infection sites
Often no
pathogens are
detected
False
alarms due
to colonization
Prolonged
time to results
Poor performance
for emerging
pathogens
How MeMed BV® Supports Sepsis Diagnosis and Management
Early differentiation between bacterial and viral infections offers additive diagnostic value on top of other existing tests and holds potential to improve antimicrobial stewardship.
Three Biomarkers + Machine
Learning = MeMed BV
15 Minutes. 3 Biomarkers. 1 Score.
From a small serum or venous whole blood sample,* the FDA-cleared MeMed BV® delivers actionable results in 15 minutes. No guessing. No waiting. Just clarity when treatment decisions can’t wait.
Advanced Science. Simple Answers.
MeMed BV® turns complex immune signals into one clear result. Powered by machine learning and three host-response biomarkers—TRAIL, IP-10, and CRP—it tells you: bacterial or viral. Fast.
Clarity from Host Response
Behind MeMed BV® is a powerful algorithm that turns host protein levels into one easy-to-read score—helping clinicians act fast, with confidence and precision.
How to Read Your MeMed BV® Score
MeMed BV Performance
MeMed BV® performance has been independently confirmed through blinded validation and real-world evidence across more than 20,000 patients. The FDA clinical study (Apollo) was conducted to establish the diagnostic performance of the MeMed BV® test for differentiating bacterial from viral infection in patients with suspected acute bacterial or viral infection.3
Consistent Accuracy Across Settings and Populations
Our unique emphasis on quality and breadth of clinical evidence sets MeMed apart. MeMed BV performance has been validated in multi-national, double-blind clinical studies and real world settings enrolling almost 20,000 subjects in Europe, Israel and the United States.3-13 These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes.
Your Success Starts Here!
Dive into the Adoption Guide and let’s streamline your implementation process together.
Download the adoption guide!
References
- Centers for Disease Control and Prevention. Antibiotic use in the United States: Progress and opportunities, 2018 update. Centers for Disease Control and Prevention, Atlanta, GA. 2018.
- Kornblith AE, Fahimi J, Kanzaria HK, Wang RC. Predictors for under-prescribing antibiotics in children with respiratory infections requiring antibiotics. Am J Emerg Med. 2018 Feb;36(2):218-225. doi: 10.1016/j.ajem.2017.
- MeMed data on file. Based on secondary endpoint analysis in Apollo Clinical Study (NCT04690569).
- Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PloS One. 2015 Mar 18;10(3):e0120012.
- van Houten CB, de Groot JA, Klein A, Srugo I, Chistyakov I, de Waal W, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): A double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr 1;17(4):431-40.
- Srugo I, Klein A, Stein M, Golan-Shany O, Kerem N, Chistyakov I, et al. Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017 Oct 1;140(4).
- Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect. 2016 Aug 1;73(2):177-80.
- Mor M, Paz M, Amir L, Levy I, Scheuerman O, Livni G, et al. Bacterial vs viral etiology of fever: A prospective study of a host score for supporting etiologic accuracy of emergency department physicians. PLoS One. 2023 Jan 30;18(1):e0281018.
- Papan C, Argentiero A, Porwoll M, Hakim U, Farinelli E, Testa I, et al. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: A prospective, multicentre cohort study. Clin Microbiol Infect. 2022 May 1;28(5):723-30.
- Halabi S, Shiber S, Paz M, Gottlieb TM, Barash E, Navon R, et al. Host test based on TRAIL, IP-10 and CRP for differentiating bacterial and viral respiratory tract infections in adults: Diagnostic accuracy study. Clin Microbiol Infect. 2023 Jun 1.
- Chokkalla AK, Tam E, Liang R, Cruz AT, Devaraj S. Validation of a multi-analyte immunoassay for distinguishing bacterial vs. viral infections in a pediatric cohort. Clin Chim Acta. 2023 Jun 1;546:117387.
- Kalmovich B, Rahamim-Cohen D, Shapiro Ben David S. Impact on patient management of a novel host response test for distinguishing bacterial and viral infections: Real world evidence from the urgent care setting. Biomedicines. 2023 May 22;11(5):1498.
- Klein A, Shapira MA, Lipman-Arens S, Bamberger E, Srugo I, Chistyakov I, et al. Diagnostic accuracy of a real-time host-protein test for infection. Pediatrics. 2023 Dec 1;152(6):e2022060441.